$25.66
0.12% yesterday
Nasdaq, Aug 21, 10:18 pm CET
ISIN
US92686J1060
Symbol
VKTX

Viking Therapeutics, Inc. Stock price

$25.66
-6.28 19.66% 1M
-8.41 24.68% 6M
-14.58 36.23% YTD
-39.10 60.38% 1Y
+22.13 626.91% 3Y
+17.73 223.58% 5Y
+19.49 315.88% 10Y
+16.70 186.38% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
-0.03 0.12%
ISIN
US92686J1060
Symbol
VKTX
Industry

Key metrics

Basic
Market capitalization
$2.9b
Enterprise Value
$2.1b
Net debt
positive
Cash
$807.7m
Shares outstanding
112.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 1,925.8
EV/Sales
- | 1,387.3
EV/FCF
negative
P/B
3.6
Financial Health
Equity Ratio
96.9%
Return on Equity
-12.5%
ROCE
-26.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $1.5m
EBITDA
$-212.4m | $-300.3m
EBIT
$-212.8m | $-264.3m
Net Income
$-171.6m | $-216.5m
Free Cash Flow
$-152.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-70.6% | -99.4%
EBIT
-70.7% | -75.2%
Net Income
-77.3% | -96.8%
Free Cash Flow
-112.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -20,020.5%
EBIT
-
Net
- | -14,429.9%
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-1.4
Short interest
30.6%
Employees
46
Rev per Employee
$0.0
Show more

Is Viking Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Viking Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Viking Therapeutics, Inc. forecast:

22x Buy
88%
3x Hold
12%

Analyst Opinions

25 Analysts have issued a Viking Therapeutics, Inc. forecast:

Buy
88%
Hold
12%

Financial data from Viking Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
52% 52%
-
- Research and Development Expense 155 155
79% 79%
-
-212 -212
71% 71%
-
- Depreciation and Amortization 0.42 0.42
180% 180%
-
EBIT (Operating Income) EBIT -213 -213
71% 71%
-
Net Profit -172 -172
77% 77%
-

In millions USD.

Don't miss a Thing! We will send you all news about Viking Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viking Therapeutics, Inc. Stock News

Neutral
The Motley Fool
about 18 hours ago
As of Aug. 20, shares of Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting to new clinical trial results regarding its oral obesity candidate, tentatively named VK2735.
Neutral
Seeking Alpha
one day ago
Viking Therapeutics' stock plunged over 40% after misunderstood Phase 2 oral weight-loss drug data, despite results showing strong short-term efficacy versus market leaders. The Phase 2 trial demonstrated 12.2% weight loss in 13 weeks, with progressive results and potential for further improvement with longer dosing periods. Concerns over high discontinuation and GI side effects are noted, but ...
Positive
The Motley Fool
one day ago
Shares of Viking Therapeutics (VKTX 7.18%) rose by almost 10% at 11 a.m. ET today. This follows a significant fall the previous day on the release of its eagerly awaited top-line results from a phase 2 trial of its weight loss drug VK2735 in oral form.
More Viking Therapeutics, Inc. News

Company Profile

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Brian Lian
Employees 46
Founded 2012
Website vikingtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today